// App-Quantinova.ai

TPS7051 : A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

Researchers

Presenter

  • Sharif S. Khan

Principal Investigators

  • Shahram Mori

  • Deepa Jeyakumar

  • Michael Kenneth Keng

  • Hemant S. Murthy

  • Michal Bar-Natan

  • Krishna Gundabolu

  • Kristen M. O'Dwyer

  • Tulio Rodriguez

  • Anthony Selwyn Stein

  • Wendy Stock

  • Caspian Oliai

  • Christopher McCann

  • Faraz Zaman

  • Gerhard Zugmaier

  • Paul Gordon

  • Timothy S. Pardee

Medical Centers

  • St. Francis Hospital, Greenville, SC

  • Adventist Health System/Sunbelt, Inc d/b/a AdventHealth Orlando, Orlando, FL

  • University of California Irvine Medical Center, Orange, CA

  • University of Virginia Medical Center, Charlottesville, VA

  • Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Nebraska Medical Center, Omaha, NE

  • University of Rochester Medcal Center, Rochester, NY

  • Advocate Lutheran General Hospital, Park Ridge, IL

  • City of Hope National Medical Center, Duarte, CA

  • The University of Chicago Medical Center, Chicago, IL

  • University of California, Los Angeles, Los Angeles, CA

  • Current Health, Edinburgh, United Kingdom

  • Amgen Inc, Thousand Oaks, CA

  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • IV

Study Id's

  • NCT04506086

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved